SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Oosterlinck W., Kurth KH, Schroeder F., Bultinck J, Hammond B, Sylvester RM, and Members of the European Organization for Research and Treatment of Cancer Genitourinary Group. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intra–vesicular instillation of epirubicin or water in single state Ta, Tl papillary carcinoma of the bladder. J Urol 1992; 149: 749752.
  • 2
    Montie JE, Wood DP Jr, Vanderbrug Mendendorp S, Levin HS, Pontes JE. The significance and management of transitional cell carcinoma of the prostate. Semin Urol 1990; 8(4): 262268.
  • 3
    Cutler SJ, Heney NM, Fnedell GH. Longitudinal study of patients with bladder cancer. Factors associated with disease recurrence and progression. In: BonneyWW, ProutGR (eds) AUA Monographs: Bladder Cancer. Baltimore : Williams and Wilkins, 1982; 1 3546.
  • 4
    Heney NM, Ahmed S., Flanagan MJ et al., Superficial bladder cancer. Progression and recurrence. J Urol 1983; 130: 1083.
  • 5
    Kaye KW, Lange PH. Mode of presentation of invasive bladder cancer. Reassessment of the problem. J Urol 1982; 128: 31.
  • 6
    Althausen AF, Prout GR Jr., Daly JJ. Non–invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976; 116: 575.
  • 7
    Prout GR Jr, Barton BA, Griffin P. et al., Treated history of non–invasive grade one transitional cell carcinoma. J Urol (in press).
  • 8
    Greene LF, Hanash KA, Farrow GM. Benign papilloma or papillary carcinoma of the bladder J Urol 1973; 10: 205.
  • 9
    National Bladder Cancer Collaborative Group A. Surveillance, initial assessment, and subsequent progress of patients with superficial bladder cancer in a prospective longitudinal study. Cancer Res 1977; 37: 2907.
  • 10
    Lamm DL. Long–term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992; 19: 573508.
  • 11
    Lamm DL. Carcinoma in situ. Urol Clin North Am 1992; 19: 4099508.
  • 12
    Riddle PR, Chishol, GD, Trott PA et al., flat carcinoma in situ of bladder. Br J Urol 1976; 47: 829.
  • 13
    Utz DC, Farrow GM. Management of carcinoma in situ of the bladder: The case for surgical management. Urol Clin North Am 1980; 7: 533541.
  • 14
    Lamm DL, Griffith JG. The place of intravesical chemotherapy as defined by results of prospective randomized studies (substances and treatment schemes). In: SchroederFH (ed) EORTC Genitourinary Group Monograph 11, Recent Progress in Bladder and Kidney Cancer. New York : Wiley–Liss, 1992; 4353.
  • 15
    Traynelis CL, Lamm DL. Current status of intravesical therapy for bladder cancer. In: RousS. (ed) 1994 Urology Annual (vol 8). New York : WW Norton & Co, 1994; 113143.
  • 16
    Akaza H., Koiso K., Kotake T. et al., Long–term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for adriamycin. Cancer Chemother Pharmacol 1992; 30(suppl): S15.
  • 17
    Huland H., Kloppel G., Feddersen I. et al., Comparison of different schedules of cystostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. J Urol 1990; 144: 68.
  • 18
    Flamm J. Long–term versus short–term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer. Eur Urol 1990; 17: 119.
  • 19
    Freidman D., Mooppan UM, Rosen Y. et al., The effect of intravesical instillations of thiotepa, mitomycin C, and adriamycin on normal urothelium: an experimental study in rats. J Urol 1991; 145: 1060.
  • 20
    Soloway MS, Matheny RB, Murphy WM. Is mitomycin C (MMC) a urothelial carcinogen AUA Annual Meeting 1983. Abstract No 352.
  • 21
    Herr HW, Laudone VP, Whitmore WF. An overview of intravesical therapy for superficial bladder tumors. J Urol 1987; 138: 1363.
  • 22
    Sosnowski JT, Lamm DL. Immunotherapy for bladder cancer. In: RousSN (ed) Urology Annual. Connecticut : Apppleton & Lange, 1990; 4: 123156.
  • 23
    Pagano F., Bassi P., Milani C. et al., A low dose bacillus Calmette–Guerin regimen in superficial bladder cancer therapy: Is it effective J Urol 1991; 146: 32.
  • 24
    Lamm DL. Bacillus Calmette–Guerin immunotherapy for bladder cancer. J Urol 1985; 134: 40.
  • 25
    Herr HW. Use of Bacillus Calmette–Guerin vaccine. In: SolowayMS, PaulsonDF (eds). Problems in Urology: Transitional Cell Malignancy. Philadelphia , PA : JB Lippincott, 1992; (6) 484492.
  • 26
    Cookson MS, Sarosdy MF. Management of stage Tl superficial bladder cancer–with intravesical bacillus Calmette–Guerin therapy. J Urol 1992; 148: 797.
  • 27
    Herr HW, Laudone VP, Badalament RA et al., Bacillus Calmette–Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988; 6: 1450.
  • 28
    Herr HW. Transurethral resection and intravesical therapy of superficial bladder tumors. In: FairWR (ed) Urol Clin N Am. Philadelphia : WB Saunders, 1990; 18: 525528.
  • 29
    Lamm DL, Crissman J., Blumenstein B., Crawford ED, Alontie J., Scardino P., Grossman HB, Stanisic T., Smith J., Sullivan J., Sarosdy M. Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group study. Prog Clin Biol Res 1989; 310: 263270.
  • 30
    Lamm DL. Immunotherapy versus chemotherapy in the treatment of superficial bladder tumors. In: AldersonAR, OliverRTD, HanhamIW, BloomHJG (eds) Urologic Oncology: Dilemmas and Developments. London : John Wiley & Sons, 1991; 107117.
  • 31
    Jauhiainen K., Rintala E., Alfthan O., The Finnbladder Group. Immunotherapy (BCG) versus chemotherapy (MMC) in intravesical treatment of superficial urinary bladder cancer. In: deKernionJB (ed) Immunotherapy of Urological Tumors. Edinburgh : Churchill Livingstone, 1990; 1326.
  • 32
    Debruyne FMJ, van der Meijden AP, Geboers AD, Franssen MP, van Leeuwen MJ, Steerenberg PA, de Jong WH, Ruitenberg JJ. BCG–RIVM versus mitomycin C intravesical therapy superficial bladder cancer. Urology 1988; 31(suppl 3): 2025.
  • 33
    Witjes JA, van der Meijden AP, Witjes WP, Doesburg W., Schaafsma HE, Debruyne FM. A randomised prospective study comparing intravesical instillations of mitomycin C, BCG–Tice, and BCG–RIVM in pTa, pTl tumors and primary carcinoma in situ of the urinary bladder. Dutch South–East Cooperative Urological Group. Eur J Cancer 1993; 29A(12): 1672–1676.
  • 34
    Rubben H., Graf–Dobberstein C, Ostwald R. Prospective randomized study of adjuvant therapy after complete resection of superficial bladder cancer: mitomycin C vs. BCG Connaught vs. TUR alone. In: deKernionJB (ed) Immunotherapy of Urological Tumors. Edinburgh : Churchill Livingstone, 1990; 27.
  • 35
    Lamm DL, Crawford Ed, Blumenstein B., Crissman J., de Vere White R., Wolf M., Lowe BM, Sarosdy M., Schellhammer P., Sagalowsky A., Smith J., Grossman HB, Flanigan R., Moon T., Brendler C., Coltman C. SWOG 8795: A randomized comparison of bacillus Calmette–Guerin and mitomycin C prophylaxis in stage TA and Tl transitional cell carcinoma of the bladder. J Urol 1993; (149(4): 275.
  • 36
    Sarosdy M., Lamm DL, Williams RD, Moon TD, Flanigan R., Crawford ED, Wilks NE, Earhart RH, Merritt JA. Phase I trial of oral bropirimine in superficial bladder cancer. J Urol 1992; 147: 3133.
  • 37
    Lamm DL, Riggs D., Shriver J., VanGilder P., Rach J., DeHaven J. Randomized double–blind comparison of high and recommended dose vitamins in superficial bladder cancer. J Urol 1993; 149: 283A(279).
  • 38
    Aso Y., Akaza H. Prophylactic effect of a lactobacillus casei preparation on the recurrence of superficial bladder cancer. Urol Int 1992; 49: 125129.